, Volume 51, Issue 2, pp 114–119 | Cite as

Effects of Eugenol on Alzheimer’s Disease-like Manifestations in Insulin- and Aβ-Induced Rat Models

  • P. Taheri
  • P. YaghmaeiEmail author
  • H. Sepasi Tehrani
  • A. Ebrahim-HabibiEmail author

Eugenol is a phenylpropene having antidepressant properties. We investigated the effect of eugenol on amyloid plaques as a hallmark of Alzheimer’s disease (AD) in two AD rat models. In the latter, betaamyloid (Aβ) and insulin amyloid fibrils were injected into the rat hippocampus. After a one week lapse, the rats were treated with 0.01 and 0.02 mg/kg eugenol for two weeks. Passive avoidance learning and memory performance was assessed by measuring the step-through latency (STL). Amyloid plaques in the hippocampus were quantitatively evaluated and statistically analyzed using image processing software and ANOVA. Aβ amyloid was a more potent inducer of the signs related to Alzheimer’s disease than insulin. Eugenol at a 0.01 mg/kg dose improved memory and reduced the number of amyloid plaques significantly (P < 0.001). Possible mechanisms are proposed for the inhibitory effects of eugenol on hippocampus plaques.


Alzheimer’s disease eugenol amyloid plaques rat hippocampus step-through latency (STL) thioflavin S 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. J. Selkoe and P. Lansbury, Alzheimer’s Disease Is the Most Common Neurodegenerative Disorder, Lippincott-Raven, Philadelphia (1999).Google Scholar
  2. 2.
    C. A. Thompson, K. Spilsbury, J. T. Hall, et al., “Systematic review of information and support interventions for caregivers of people with dementia,” BMC Geriatr., 7, No. 1, 18 (2007).CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    M. Medina, Z. S. Khachaturian, M. Rossor, et al., “Toward common mechanisms for risk factors in Alzheimer’s syndrome,” Alzheimers Dement. (N.Y.), 3 , No. 4, 571–578 (2017).Google Scholar
  4. 4.
    H. Eichenbaum, A. P. Yonelinas, and C. Ranganath, “The medial temporal lobe and recognition memory,” Annu. Rev. Neurosci., 30, 123–152 (2007).CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Y.-L. Gao, N. Wang, F.-R. Sun, et al., “Tau in neurodegenerative disease,” Ann. Transl. Med., 6, No. 10, 175 (2018).CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    E. Tönnies and E. Trushina, “Oxidative stress, synaptic dysfunction, and Alzheimer’s disease,” J. Alzheimers Dis., 57, No. 4, 1105–1121 (2017).CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    J. Barnes, L. A. Anderson, and J. D. Phillipson, Herbal Medicines, Pharmaceutical Press, London (2007).Google Scholar
  8. 8.
    B. K. Jadhav, K. R. Khandelwal, A. R. Ketkar, and S. S. Pisal, “Formulation and evaluation of mucoadhesive tablets containing eugenol for the treatment of periodontal diseases,” Drug Dev. Ind. Pharm., 30, No. 2, 195–203 (2004).CrossRefPubMedGoogle Scholar
  9. 9.
    G. Tao, Y. Irie, D.-J. Li, and W. M. Keung, “Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity,” Bioorg. Med. Chem., 13, No. 15, 4777–4788 (2005).CrossRefPubMedGoogle Scholar
  10. 10.
    Z. Liu, W. Niu, X. Yang, and Y. Wang, “Effects of combined acupuncture and eugenol on learning-memory ability and antioxidation system of hippocampus in Alzheimer disease rats via olfactory system stimulation,” J. Trad. Chin. Med., 33, No. 3, 399–402 (2013).CrossRefGoogle Scholar
  11. 11.
    M. Bouchard, J. Zurdo, E. Nettleton, et al., “Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy,” Protein Sci., 9, No. 10, 1960–1967 (2000).CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    G. Paxinos and C. Watson, The Rat Brain Atlas in Stereotaxic Coordinates, Acad. Press, San Diego (1998).Google Scholar
  13. 13.
    F. Cetin and S. Dincer, “The effect of intrahippocampal beta amyloid (1-42) peptide injection on oxidant and antioxidant status in rat brain,” Ann. N.Y. Acad. Sci., 1100, No. 1, 510–517 (2007).CrossRefPubMedGoogle Scholar
  14. 14.
    R. Kheirbakhsh, M. Chinisaz, S. Khodayari, et al., “Injection of insulin amyloid fibrils in the hippocampus of male Wistar rats: report on memory impairment and formation of amyloid plaques,” Neurol. Sci., 36, No. 8, 1411–1416 (2015).CrossRefPubMedGoogle Scholar
  15. 15.
    J.-H. Bach, H. S. Chae, J. C. Rah, et al., “C-terminal fragment of amyloid precursor protein induces astrocytosis,” J. Neurochem., 78, No. 1, 109–120 (2001).CrossRefPubMedGoogle Scholar
  16. 16.
    E. Solito and M. Sastre, “Microglia function in Alzheimer’s disease,” Front. Pharmacol., 3, No. 14 (2012), doi:
  17. 17.
    S. A. Frautschy, F. Yang, L. Calderón, and G. M. Cole, “Rodent models of Alzheimer’s disease: rat Aβ infusion approaches to amyloid deposits,” Neurobiol. Aging, 17, No. 2, 311–321 (1996).CrossRefPubMedGoogle Scholar
  18. 18.
    H. Ramshini, A. S. Moghaddasi, L. S. Aldaghi, et al., “Silver nano particles ameliorate learning and spatial memory of male Wistar rats by prevention of amyloid fibril-induced neurotoxicity,” Arch. Ital. Biol., 155, No. 3, 131–141 (2017).PubMedGoogle Scholar
  19. 19.
    M. Stefani and S. Rigacci, “Protein folding and aggregation into amyloid: the interference by natural phenolic compounds,” Int. J. Mol. Sci., 14, No. 6, 12411–12457 (2013).CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    K. Balasubramanian, “Molecular orbital basis for yellow curry spice curcumin’s prevention of Alzheimer’s disease,” J. Agric. Food Chem., 54, No. 10, 3512–3520 (2006).CrossRefPubMedGoogle Scholar
  21. 21.
    S. A. Hudson, H. Ecroyd, F. C. Dehle, et al., “(−)-Epigal-locatechin-3-gallate (EGCG) maintains κ-casein in its pre-fibrillar state without redirecting its aggregation pathway,” J. Mol. Biol., 392, No. 3, 689–700 (2009).CrossRefPubMedGoogle Scholar
  22. 22.
    M. Dumont and M. F. Beal, “Neuroprotective strategies involving ROS in Alzheimer disease,” Free Radic. Biol. Med., 51, No. 5, 1014–1026 (2011).CrossRefPubMedGoogle Scholar
  23. 23.
    R. Deane and B. V. Zlokovic, “Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease,” Curr. Alzheimer Res., 4, No. 2, 191–197 (2007).CrossRefPubMedGoogle Scholar
  24. 24.
    Y. Irie, N. Itokazu, N. Anjiki, et al., “Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus,” Brain Res., 1011, No. 2, 243–246 (2004).CrossRefPubMedGoogle Scholar
  25. 25.
    S. Dohi, M. Terasaki, and M. Makino, “Acetylcholinesterase inhibitory activity and chemical composition of commercial essential oils,” J. Agric. Food Chem., 57, No. 10, 4313–4318 (2009).CrossRefPubMedGoogle Scholar
  26. 26.
    E. Paradis, H. Douillard, M. Koutroumanis, et al., “Amyloid β peptide of Alzheimer’s disease downregulates Bcl-2 and upregulates Bax expression in human neurons,” J. Neurosci., 16, No. 23, 7533–7539 (1996).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Biology, Science and Research BranchIslamic Azad UniversityTehranIran
  2. 2.Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences InstituteTehran University of Medical SciencesTehranIran
  3. 3.Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences InstituteTehran University of Medical SciencesTehranIran

Personalised recommendations